Clover Health reports 53% Medicare Advantage membership growth, aiming for GAAP Net Income profitability in 2026 through improved cohort performance.
Quiver AI Summary
Clover Health Investments, Corp. announced impressive growth in its Medicare Advantage plans, reporting a 53% year-over-year increase in membership for 2026, totaling approximately 153,000 members. This growth is attributed to disciplined market strategies, strong member retention, and improvements in cohort economics, positioning Clover on track for its first-ever GAAP Net Income profitability in 2026. Over 97% of Clover's members are enrolled in its highly rated PPO plan, which leads nationally in key quality metrics. The company emphasizes its commitment to quality care through its Clover Assistant technology, which enhances clinical outcomes. CEO Andrew Toy expressed optimism about Clover's financial trajectory, hoping to leverage their sustainable growth to enhance earnings and margins while maintaining stable benefits and strong member loyalty.
Potential Positives
- Clover reported a significant 53% year-over-year membership growth in its Medicare Advantage PPO plans, indicating strong demand for its offerings against industry trends.
- The company anticipates achieving its first-ever full year GAAP Net Income profitability in 2026, signifying a positive financial trajectory and operational efficiency.
- Over 97% of Clover’s January 1, 2026 membership is in its flagship PPO plan, which is ranked #1 nationally for clinical quality, demonstrating strong performance and member satisfaction.
Potential Negatives
- Despite reporting a 53% increase in membership, the company is entering 2026 amid a broader industry retreat, which raises questions about its sustainability and competitive positioning in a challenging market.
- The reliance on forward-looking statements regarding achieving GAAP Net Income profitability in 2026 may create investor skepticism, especially given the inherent risks and uncertainties outlined in the release.
- The press release emphasizes the importance of Clover Assistant for growth and efficiency, which may expose the company to risks if the anticipated adoption and success of this technology do not meet expectations.
FAQ
What is Clover Health's membership growth rate for 2026?
Clover Health reports a 53% year-over-year membership growth rate in its Medicare Advantage PPO plans for 2026.
When does Clover Health expect to achieve GAAP Net Income profitability?
Clover Health expects to achieve its first-ever full year GAAP Net Income profitability in 2026.
What percentage of Clover's members are in the top-ranked PPO plan?
Over 97% of Clover's January 1, 2026 membership is in its flagship PPO plan, which is ranked #1 nationally.
How does Clover Health maintain strong member retention?
Clover Health maintains strong member retention through stable plan benefits and a focus on member engagement and support.
What technology powers Clover Health's clinical quality?
Clover Health's clinical quality is powered by their software platform, Clover Assistant, enhancing decision-making and healthcare outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLOV Insider Trading Activity
$CLOV insiders have traded $CLOV stock on the open market 13 times in the past 6 months. Of those trades, 4 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:
- VIVEK GARIPALLI has made 2 purchases buying 446,980 shares for an estimated $998,996 and 0 sales.
- CONRAD WAI (CEO, Counterpart Health) has made 0 purchases and 2 sales selling 209,797 shares for an estimated $692,968.
- JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 7 sales selling 67,663 shares for an estimated $211,576.
- ANNA U LOENGARD has made 2 purchases buying 26,500 shares for an estimated $68,755 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLOV Revenue
$CLOV had revenues of $496.6M in Q3 2025. This is an increase of 50.05% from the same period in the prior year.
You can track CLOV financials on Quiver Quantitative's CLOV stock page.
$CLOV Hedge Fund Activity
We have seen 88 institutional investors add shares of $CLOV stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ removed 3,879,613 shares (-96.7%) from their portfolio in Q3 2025, for an estimated $11,871,615
- MARSHALL WACE, LLP removed 3,523,047 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,780,523
- RENAISSANCE TECHNOLOGIES LLC removed 2,780,900 shares (-26.5%) from their portfolio in Q3 2025, for an estimated $8,509,554
- DIVISADERO STREET CAPITAL MANAGEMENT, LP added 2,768,088 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,470,349
- CITADEL ADVISORS LLC removed 2,042,721 shares (-57.9%) from their portfolio in Q3 2025, for an estimated $6,250,726
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,746,937 shares (-82.6%) from their portfolio in Q3 2025, for an estimated $5,345,627
- GOLDMAN SACHS GROUP INC removed 1,494,774 shares (-63.3%) from their portfolio in Q3 2025, for an estimated $4,574,008
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLOV Analyst Ratings
Wall Street analysts have issued reports on $CLOV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for $CLOV, check out Quiver Quantitative's $CLOV forecast page.
$CLOV Price Targets
Multiple analysts have issued price targets for $CLOV recently. We have seen 2 analysts offer price targets for $CLOV in the last 6 months, with a median target of $3.35.
Here are some recent targets:
- Richard Close from Canaccord Genuity set a target price of $3.7 on 11/06/2025
- Jonathan Yong from UBS set a target price of $3.0 on 08/06/2025
Full Release
- Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income profitability in 2026.
- Disciplined, core-market growth, strong returning member retention, and improving cohort economics position Clover for compounding earnings and margin expansion.
-
Powered by AI, Clover continues to bring industry-leading clinical quality to members, with ~97% of Clover’s January 1, 2026 membership in flagship PPO plan that is ranked #1 nationally on core HEDIS metrics.
WILMINGTON, Del., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced 53% year-over-year membership growth in its Medicare Advantage (MA) PPO plans for the 2026 plan year. Following this strong Annual Enrollment Period (AEP), Clover enters 2026 with approximately 153,000 members , reflecting disciplined growth primarily in core markets, with strong retention, supporting Clover’s path toward expected full year 2026 GAAP Net Income profitability.
Key AEP and Business Highlights:
- Strategic Growth: Clover reports a 53% Medicare Advantage membership increase year-over-year, achieved amidst a broader industry retreat, which is concentrated in established core markets where the Company maintains strong Clover Assistant (CA) coverage and a differentiated Home Care offering to deliver better care and drive improving cohort performance.
- Expects Full Year 2026 GAAP Net Income Profitability: Clover expects to be positioned to achieve first-ever Full Year GAAP Net Income profitability driven by strong cohort economics and efficiencies from continued SG&A leverage and optimization.
-
Strong Visibility into Cohort Economics Improvement:
Clover anticipates meaningful new member cohort improvement and continued strong returning cohort performance, complementing sustained growth and supported by:
- Financial impact of 4.0 Stars during payment year 2026 for Clover’s PPO plans,
- Favorable 2026 CMS final rate update & increased Part D direct subsidy,
- Strong returning member retention,
- Focus on increasing Clover Assistant coverage & PCP adoption, and
- Continued operating leverage as SG&A efficiency improves with scale.
- Stable Benefits & Strong Member Retention: Clover strategically maintained stable plan benefits year-over-year, delivering >95% AEP member retention. This reinforces the stability of the Company’s membership base and the enduring value of Clover plan offerings to attract and retain members. This led to intentional PPO growth, with the vast majority of Clover's new membership being MA switchers located within core markets, as expected.
-
Industry-Leading Quality:
>97% of Clover’s January 1, 2026 MA membership is in its flagship PPO plan, which is ranked as the #1 PPO plan nationally on core HEDIS quality measures for the second year in a row
1
, reinforcing the strength of Clover’s clinical and economic performance.
"This year’s AEP performance shows what happens when robust plan benefits, Clover Assistant-enabled clinical performance, and a deepening market presence in local communities come together,” said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. “We have replicated our AEP growth playbook from last year, and are proud to have exceeded our expectations in delivering market-leading growth this enrollment period. This is a direct result of targeted, sustainable, and concentrated growth in our core markets where we continue to scale Clover Assistant and Home Care to meet members where they are.”
"We are entering 2026 on a strong financial trajectory," said Andrew Toy, Chief Executive Officer of Clover Health . "We believe this year will demonstrate the full power of Clover’s model: significant member growth and strong returning member retention, layered onto meaningfully improving cohort performance and the continued impact of Clover Assistant. Together, we believe these dynamics will create compounding earnings and margin expansion over time, which we expect to position Clover to deliver its first year of GAAP Net Income profitability in 2026.”
_______________
1
This analysis focuses on performance by non-SNP PPO plans with over 2,000 lives as of September 1, 2025 on HEDIS measures applicable to non-SNPs that were used for CMS’s MY 2024 Star ratings, applying the measure ranges used by CMS.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and Clover Health’s future results of operations, financial position, business strategy and future plans. Forward-looking statements are not guarantees of future performance, and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “going to,” “can,” “could,” “should,” “would,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “outlook,” “forecast,” “guidance,” “objective,” “plan,” “seek,” “grow,” “target,” “if,” “continue” or the negative of these words or other similar terms or expressions that concern Clover’s expectations, strategy, priorities, plans or intentions. Forward-looking statements in this press release include, but are not limited to, expected 2026 GAAP Net Income profitability and Clover’s anticipated financial results associated with CMS’ Stars rating of 4.0 for Clover’s PPO MA plans for payment year 2026, its 2026 financial outlook, future membership growth and retention, Clover assistant usage and investment, CMS’ 2026 rate update, Part D direct subsidies, and cost efficiency initiatives, as well as our expectations related to Clover’s GAAP Net Income, liquidity, future performance, future operations and future results. These statements are subject to known and unknown risks, uncertainties and other factors that may cause Clover Health’s actual results, levels of activity, performance or achievements to differ materially from results expressed or implied in this press release. Forward-looking statements involve a number of judgments, risks and uncertainties, including, without limitation, risks related to: our expectations regarding results of operations, financial condition, and cash flows; our expectations regarding the development and management of our business; any current, pending, or future legislation, regulations or policies that could have a negative effect on our revenue, profit margins, cash flows and business, including rules, regulations and policies relating to healthcare, Medicare generally and medical loss ratios; our ability to successfully enter new service markets and manage our operations; anticipated trends and challenges in our business and in the markets in which we operate; our ability to effectively manage our beneficiary base and provider network; our ability to maintain and increase adoption and use of Clover Assistant, including the expansion of Clover Assistant for external payors and providers under the brand name Counterpart Assistant; the anticipated benefits associated with the use of Clover Assistant, including our ability to utilize the platform to manage our medical expenses; our ability to maintain or improve our Star Ratings or otherwise continue to improve the financial performance of our business; our ability to develop new features and functionality that meet market needs and achieve market acceptance; our ability to retain and hire necessary employees and staff our operations appropriately; the timing and amount of certain investments in growth; the outcome of any known and unknown litigation and regulatory proceedings; our ability to maintain, protect, and enhance our intellectual property; general economic conditions and uncertainty; persistent high inflation and fluctuating interest rates; and geopolitical uncertainty and instability. Additional information concerning these and other risk factors is contained in Clover Health’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2025, and in our subsequent filings with the SEC, in each case where relevant, including the Risk Factors sections therein, and in its other filings with the SEC. The forward-looking statements included in this press release are made as of the date hereof. Except as required by law, Clover Health undertakes no obligation to update any of these forward-looking statements after the date of this press release or to conform these statements to actual results or revised expectations.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on
Medication Adherence
,
Congestive Heart Failure
,
Chronic Obstructive Pulmonary Disease
, and in
Underserved Populations
as well as the earlier identification and management of
Diabetes
and
Chronic Kidney Disease
.
Investor Relations:
Ryan Schmidt
[email protected]
Press Inquiries:
[email protected]